Navigation Links
US Patent awarded for using Metal Peptides to Help Diminish Skin Imperfections
Date:7/11/2012

BELLEVUE, Wash., July 11, 2012 /PRNewswire/ -- Summit Associates International today announced that it was awarded US Patent 8,183,204, on methods and compositions for increasing skin remodeling. The patent describes the use of metal peptides for helping to diminish or remove various skin imperfections, including wound and surgical scars, acne scars, keloids, skin tags, benign skin moles, stretch marks, facial keratosis, sunspots, or a vitiligo.

The inventor, Dr. Loren Pickart, previously discovered the human skin-remodeling, copper-binding peptide GHK, and then developed clinically-proven methods for its use in cosmetic skin improvement, hair growth, and hair transplantation. Recent published work from numerous universities found that GHK controls or heavily influences 17% of the human genome, and also possesses a multiplicity of "wellness" properties including regeneration of tissues, activation of quiescent stem cells, suppression of numerous cancer metastasis genes, plus anti-inflammatory and anti-infection actions.

"The real cause of aging and most diseases is the silencing of regenerative and protective genes," said Dr. Pickart, "At age 25, our genes produce the healthiest mix of proteins, then gene silencing reduces the effect of our regenerative genes and increases the influence inflammatory and cancer-promoting genes. Summit Associates is also focused on developing and patenting methods of re-programming the human gene pattern to inhibit cancer growth and the effects of human senescence."

Summit Associates is Dr. Pickart's research group and located in Bellevue, WA. More information can be found at www.summit-associates-intl.com


Media contact:
Dr. Loren Pickart
425-644-0160
Email lorenpickart@summit-associate-intl.com


'/>"/>
SOURCE Summit Associates International
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Enbrel® (etanercept) Patent Issued
2. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
3. Cenestra Health Announces Granting of Broad Patent Covering Proprietary Bioactive Lipid Formulations
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties Misleading Patent Assertions
6. Bio-AMD, Inc.; DSR Commercial Refinement, Prospective Patent Applications
7. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
8. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
9. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
10. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
11. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017   Sienna Biopharmaceuticals, Inc. , a privately ... that Richard Peterson will join the company ... Peterson, who brings more than two decades of global ... is retiring at the end of April but will ... joins Sienna from Novan, Inc., where he served as ...
(Date:3/23/2017)... BETHESDA, Md. , March 23, 2017 /PRNewswire/ ... company developing DCVax® personalized immune therapies for solid ... on the $7.5 million financing it announced last ... Company sold to several institutional investors securities totaling ... $.26 per share, and 10,000,000 shares of Class ...
(Date:3/23/2017)... 2017 Kineta, Inc., a biotechnology company ... in immuno-oncology, today announced the discovery and characterization ... that activate interferon response factor 3 (IRF3) via ... tumor regression in a murine colon carcinoma mouse ... complete tumor regression to initial drug treatment were ...
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced ... the hire of Dr. Sigmund “Sig” Floyd as Vice President ? Global Business ... joint development activities. , “Dr. Floyd’s career has spanned 30 years in the ...
Breaking Biology Technology:
(Date:3/2/2017)... LONDON , March 2, 2017 Summary ... require to better understand Merck KGaA and its partnering ... report: https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals ... into the partnering activity of one of the world,s ... reports are prepared upon purchase to ensure inclusion of ...
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
(Date:2/28/2017)... 2017   Acuant , a leading provider of ... enhancements to new and core technologies building upon the ... mobile and desktop Acuant FRM TM facial recognition ... real time manual review of identity documents by accredited ... fastest and most accurate capture software to streamline workflows ...
Breaking Biology News(10 mins):